Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Neutral Recommendation
20/5 01:31
Fintel reports that on May 19, 2026, Citigroup initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Neutral recommendation. Analyst Price Forecast Suggests 59.71% Upside...